As pharmaceutical marketers increase their use of digital media to reach physicians, one business has found with a little ingenuity it can help companies discover social media channels and websites where they may not have expected to find doctors and other healthcare providers. Slideshare, anyone? SoundCloud?
Medikly, a graduate of Blueprint Health’s summer class, was founded by physician, pharmaceutical marketer and entrepreneur Dr. Venkat Gullapalli. It offers pharmaceutical marketers an integrated platform to better target their audience. Gullapalli said it’s offering a service more commonly found in the consumer arena than in the business-to-business pharmaceutical space.
“It allows organizations to understand how physicians interact with each other as well as understanding their behaviors on how they consume content. In the consumer marketing world, companies are able to narrowly target the information they send consumers — knowing what they want, what channels they are using, their intent to purchase — and that’s something that’s been missing in the pharmaceutical space or any organization that wants to target physicians and healthcare professionals.”
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
Nita Nehru, Medikly vice president of business development